A Review of Current and Future Antibody Drug Conjugates in Breast Cancer.

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI:10.1007/s11864-024-01276-3

Megan Randall, Rachel Akers, Ruta Rao

{"title":"A Review of Current and Future Antibody Drug Conjugates in Breast Cancer.","authors":"Megan Randall, Rachel Akers, Ruta Rao","doi":"10.1007/s11864-024-01276-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>Antibody-drug conjugates (ADCs) are a novel class of anti-cancer agents that have changed the standard of care for patients with breast cancer. Their targeted approach delivers potent anti-cancer drugs to cancer cells bearing specific surface antigens, thereby maximizing anti-cancer effects and minimizing systemic toxicity. Currently, there are three ADCs available for use in breast cancer: trastuzumab emtansine for HER2 positive breast cancer (early stage and metastatic), trastuzumab deruxtecan for HER2 positive and HER2 low breast cancer (metastatic) and sacituzumab govitecan for triple negative and hormone receptor positive (HR +), HER2 negative breast cancer(metastatic). Trials have shown that these drugs have improved both progression free survival and overall survival in the metastatic setting, and trastuzumab emtansine has improved overall survival in early-stage breast cancer as well. The future of this class of compounds is very exciting. This field is rapidly evolving with new ADCs being investigated and clinical trials looking at the use of known ADCs in earlier stage disease.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1506-1516"},"PeriodicalIF":3.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01276-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: Antibody-drug conjugates (ADCs) are a novel class of anti-cancer agents that have changed the standard of care for patients with breast cancer. Their targeted approach delivers potent anti-cancer drugs to cancer cells bearing specific surface antigens, thereby maximizing anti-cancer effects and minimizing systemic toxicity. Currently, there are three ADCs available for use in breast cancer: trastuzumab emtansine for HER2 positive breast cancer (early stage and metastatic), trastuzumab deruxtecan for HER2 positive and HER2 low breast cancer (metastatic) and sacituzumab govitecan for triple negative and hormone receptor positive (HR +), HER2 negative breast cancer(metastatic). Trials have shown that these drugs have improved both progression free survival and overall survival in the metastatic setting, and trastuzumab emtansine has improved overall survival in early-stage breast cancer as well. The future of this class of compounds is very exciting. This field is rapidly evolving with new ADCs being investigated and clinical trials looking at the use of known ADCs in earlier stage disease.

查看原文本刊更多论文

乳腺癌中抗体药物偶联物的现状和未来研究进展。

观点声明：抗体-药物偶联物（adc）是一类新型抗癌药物，已经改变了乳腺癌患者的护理标准。他们的靶向方法将有效的抗癌药物输送到具有特定表面抗原的癌细胞中，从而最大限度地提高抗癌效果并最小化全身毒性。目前，有三种adc可用于乳腺癌：曲妥珠单抗emtansine用于HER2阳性乳腺癌（早期和转移性），曲妥珠单抗deruxtecan用于HER2阳性和HER2低水平乳腺癌（转移性），以及sacituzumab govitecan用于三阴性和激素受体阳性（HR +）， HER2阴性乳腺癌（转移性）。试验表明，这些药物改善了转移性乳腺癌的无进展生存期和总生存期，曲妥珠单抗emtansine也改善了早期乳腺癌的总生存期。这类化合物的未来是非常令人兴奋的。这一领域正在迅速发展，人们正在研究新的adc，并进行临床试验，研究已知adc在早期疾病中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.